Elicio Therapeutics (ELTX) Change in Accured Expenses (2020 - 2026)

Elicio Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$602000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 77.24% year-over-year to -$602000.0; the trailing twelve-month figure through Mar 2026 stood at $55000.0 (down 97.75% YoY), and the FY2025 full-year result was -$2.0 million, down 142.68% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$602000.0, down from $1.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.6 million in Q4 2024, with the low at -$2.6 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $234058.8 across 5 years, with a median of -$179000.0 in 2022.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 1541.13% — and 2025, when it slumped 512.27%.
• Elicio Therapeutics' Change in Accured Expenses stood at -$235000.0 in 2022, then surged by 230.21% to $306000.0 in 2023, then surged by 1064.38% to $3.6 million in 2024, then sank by 65.93% to $1.2 million in 2025, then slumped by 149.59% to -$602000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$602000.0 (Q1 2026), $1.2 million (Q4 2025), and $107000.0 (Q3 2025), per Business Quant data.